The current experiments were designed to examine the protein levels of GPER-1 in ERα-positive breast cancer cells that were continuously treated with tamoxifen for a period of 7 days and to investigate the mobilization of intracellular Ca2+ and cell proliferation that follows their stimulation with tamoxifen or GPER-1 agonists. Here, GPER1 is linked to breast carcinoma.